Letter to stakeholders regarding the implementation of safety features

European Commission together with European Medicines Agency and HMA announce an important message to all stakeholders regarding the implementation of safety features under the Falsified Medicines Directive 2011/62/EU.

The Commission is very clear: “It is important that all stakeholders act now to ensure compliance with the new rules whilst there is still sufficient time to prepare.”

Please see attached letter to find more

• Letter to stakeholders on obligations_17.10.2018.pdf (221 KB)